ACR Appropriateness Criteria® thyroid carcinoma

Joseph K. Salama, Daniel W. Golden, Sue S. Yom, Madhur K. Garg, Joshua Lawson, Mark W. McDonald, Harry Quon, John A. Ridge, Nabil Saba, Richard V. Smith, Francis Worden, Anamaria Reyna Yeung, Jonathan J. Beitler

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The ACR Head and Neck Cancer Appropriateness Criteria Committee reviewed relevant medical literature to provide guidance for those managing patients with thyroid carcinoma. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Thyroid cancer is the most common endocrine malignancy in the United States, most often presenting as a localized palpable nodule. Surgery is the mainstay of treatment for WDTC, with most patients undergoing complete resection of their disease having good outcomes. Following surgery thyroxine supplementation should begin to suppress TSH, which unchecked can stimulate residual disease and/or metastatic progression, Adjuvant treatment with radioactive iodine (RAI) using iodine-131 (131I) is frequently used for diagnostic and therapeutic purposes. The use of EBRT for thyroid cancer has not been tested in well-designed, randomized, controlled trials and should, therefore, be considered on a case-by-case basis. Chemotherapy plays a minimal role in the management of WDTC. Novel biologic agents, such as systemic therapy options, are being actively investigated, and patients with metastatic thyroid cancer that is not iodine avid should be encouraged to enroll in clinical trials exploring novel systemic agents.

Original languageEnglish (US)
Pages (from-to)577-586
Number of pages10
JournalOral Oncology
Volume50
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Thyroid Neoplasms
Iodine
Therapeutics
Guidelines
Expert Testimony
Biological Factors
Head and Neck Neoplasms
Thyroxine
Radiology
Randomized Controlled Trials
Clinical Trials
Drug Therapy
Neoplasms

Keywords

  • Anaplastic thyroid cancer
  • Appropriateness Criteria
  • Medullary thyroid cancer
  • Radiotherapy thyroid cancer
  • Thyroid cancer
  • Well differentiated thyroid cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Oral Surgery
  • Medicine(all)

Cite this

Salama, J. K., Golden, D. W., Yom, S. S., Garg, M. K., Lawson, J., McDonald, M. W., ... Beitler, J. J. (2014). ACR Appropriateness Criteria® thyroid carcinoma. Oral Oncology, 50(6), 577-586. https://doi.org/10.1016/j.oraloncology.2013.12.004

ACR Appropriateness Criteria® thyroid carcinoma. / Salama, Joseph K.; Golden, Daniel W.; Yom, Sue S.; Garg, Madhur K.; Lawson, Joshua; McDonald, Mark W.; Quon, Harry; Ridge, John A.; Saba, Nabil; Smith, Richard V.; Worden, Francis; Yeung, Anamaria Reyna; Beitler, Jonathan J.

In: Oral Oncology, Vol. 50, No. 6, 2014, p. 577-586.

Research output: Contribution to journalArticle

Salama, JK, Golden, DW, Yom, SS, Garg, MK, Lawson, J, McDonald, MW, Quon, H, Ridge, JA, Saba, N, Smith, RV, Worden, F, Yeung, AR & Beitler, JJ 2014, 'ACR Appropriateness Criteria® thyroid carcinoma', Oral Oncology, vol. 50, no. 6, pp. 577-586. https://doi.org/10.1016/j.oraloncology.2013.12.004
Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW et al. ACR Appropriateness Criteria® thyroid carcinoma. Oral Oncology. 2014;50(6):577-586. https://doi.org/10.1016/j.oraloncology.2013.12.004
Salama, Joseph K. ; Golden, Daniel W. ; Yom, Sue S. ; Garg, Madhur K. ; Lawson, Joshua ; McDonald, Mark W. ; Quon, Harry ; Ridge, John A. ; Saba, Nabil ; Smith, Richard V. ; Worden, Francis ; Yeung, Anamaria Reyna ; Beitler, Jonathan J. / ACR Appropriateness Criteria® thyroid carcinoma. In: Oral Oncology. 2014 ; Vol. 50, No. 6. pp. 577-586.
@article{1c55080346c84036b00e5c87caa254ce,
title = "ACR Appropriateness Criteria{\circledR} thyroid carcinoma",
abstract = "The ACR Head and Neck Cancer Appropriateness Criteria Committee reviewed relevant medical literature to provide guidance for those managing patients with thyroid carcinoma. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Thyroid cancer is the most common endocrine malignancy in the United States, most often presenting as a localized palpable nodule. Surgery is the mainstay of treatment for WDTC, with most patients undergoing complete resection of their disease having good outcomes. Following surgery thyroxine supplementation should begin to suppress TSH, which unchecked can stimulate residual disease and/or metastatic progression, Adjuvant treatment with radioactive iodine (RAI) using iodine-131 (131I) is frequently used for diagnostic and therapeutic purposes. The use of EBRT for thyroid cancer has not been tested in well-designed, randomized, controlled trials and should, therefore, be considered on a case-by-case basis. Chemotherapy plays a minimal role in the management of WDTC. Novel biologic agents, such as systemic therapy options, are being actively investigated, and patients with metastatic thyroid cancer that is not iodine avid should be encouraged to enroll in clinical trials exploring novel systemic agents.",
keywords = "Anaplastic thyroid cancer, Appropriateness Criteria, Medullary thyroid cancer, Radiotherapy thyroid cancer, Thyroid cancer, Well differentiated thyroid cancer",
author = "Salama, {Joseph K.} and Golden, {Daniel W.} and Yom, {Sue S.} and Garg, {Madhur K.} and Joshua Lawson and McDonald, {Mark W.} and Harry Quon and Ridge, {John A.} and Nabil Saba and Smith, {Richard V.} and Francis Worden and Yeung, {Anamaria Reyna} and Beitler, {Jonathan J.}",
year = "2014",
doi = "10.1016/j.oraloncology.2013.12.004",
language = "English (US)",
volume = "50",
pages = "577--586",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - ACR Appropriateness Criteria® thyroid carcinoma

AU - Salama, Joseph K.

AU - Golden, Daniel W.

AU - Yom, Sue S.

AU - Garg, Madhur K.

AU - Lawson, Joshua

AU - McDonald, Mark W.

AU - Quon, Harry

AU - Ridge, John A.

AU - Saba, Nabil

AU - Smith, Richard V.

AU - Worden, Francis

AU - Yeung, Anamaria Reyna

AU - Beitler, Jonathan J.

PY - 2014

Y1 - 2014

N2 - The ACR Head and Neck Cancer Appropriateness Criteria Committee reviewed relevant medical literature to provide guidance for those managing patients with thyroid carcinoma. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Thyroid cancer is the most common endocrine malignancy in the United States, most often presenting as a localized palpable nodule. Surgery is the mainstay of treatment for WDTC, with most patients undergoing complete resection of their disease having good outcomes. Following surgery thyroxine supplementation should begin to suppress TSH, which unchecked can stimulate residual disease and/or metastatic progression, Adjuvant treatment with radioactive iodine (RAI) using iodine-131 (131I) is frequently used for diagnostic and therapeutic purposes. The use of EBRT for thyroid cancer has not been tested in well-designed, randomized, controlled trials and should, therefore, be considered on a case-by-case basis. Chemotherapy plays a minimal role in the management of WDTC. Novel biologic agents, such as systemic therapy options, are being actively investigated, and patients with metastatic thyroid cancer that is not iodine avid should be encouraged to enroll in clinical trials exploring novel systemic agents.

AB - The ACR Head and Neck Cancer Appropriateness Criteria Committee reviewed relevant medical literature to provide guidance for those managing patients with thyroid carcinoma. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Thyroid cancer is the most common endocrine malignancy in the United States, most often presenting as a localized palpable nodule. Surgery is the mainstay of treatment for WDTC, with most patients undergoing complete resection of their disease having good outcomes. Following surgery thyroxine supplementation should begin to suppress TSH, which unchecked can stimulate residual disease and/or metastatic progression, Adjuvant treatment with radioactive iodine (RAI) using iodine-131 (131I) is frequently used for diagnostic and therapeutic purposes. The use of EBRT for thyroid cancer has not been tested in well-designed, randomized, controlled trials and should, therefore, be considered on a case-by-case basis. Chemotherapy plays a minimal role in the management of WDTC. Novel biologic agents, such as systemic therapy options, are being actively investigated, and patients with metastatic thyroid cancer that is not iodine avid should be encouraged to enroll in clinical trials exploring novel systemic agents.

KW - Anaplastic thyroid cancer

KW - Appropriateness Criteria

KW - Medullary thyroid cancer

KW - Radiotherapy thyroid cancer

KW - Thyroid cancer

KW - Well differentiated thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=84900407857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900407857&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2013.12.004

DO - 10.1016/j.oraloncology.2013.12.004

M3 - Article

VL - 50

SP - 577

EP - 586

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 6

ER -